Clin Assoc Prof Ng Kok Pin

MBBS (Singapore), MRCP (United Kingdom), MCI (NUS)

Senior Consultant

National Neuroscience Institute

Specialty: Neurology, Neuroscience

Make an Appointment

About

Education and Training

Professional Appointments and Committee Memberships

Awards

Research Interests

Publications

Conditions Treated By This Doctor

Dementia

Clinical Interests

Cognitive Neurology, General Neurology

Clinical Appointments

Service Chief, NNI@TTSH

SingHealth Duke-NUS Centre of Memory and Cognitive Disorders

Senior Consultant

Department of Neurology

Academic Appointments

Clinical Associate Professor

Neuroscience Academic Clinical Programme

About

Assoc Prof Ng Kok Pin is a Senior Consultant at the Department of Neurology, National Neuroscience Institute and the Service Chief at NNI@TTSH for the SingHealth Duke-NUS Memory and Cognitive Disorder Centre. Assoc Prof Ng is the Assistant Director, Research (Research Program) of NNI and Executive Committee Member of the SingHealth AI Office. His research work focuses on the cognitive and behavioral aspects of neurocognitive diseases using platforms such as biomarkers, neuroimaging and MedTech.

Assoc Prof Ng holds academic appointments at the Duke-NUS Medical School, Singapore, Yong Loo Lin School of Medicine, Singapore and Lee Kong Chian School of Medicine, Singapore. He is also a Board Member for the Chapter of Neurologists, Academy of Medicine, Singapore.

Education and Training

MCI (NUS), 2015
MRCP (UK), 2011
MBBS National University of Singapore, 2006

Professional Appointments and Committee Memberships

Senior Consultant, Department of Neurology, National Neuroscience Institute
Clinical Associate Professor – Duke-NUS Medical School, Singapore
Adjunct Assistant Professor – Lee Kong Chian School of Medicine, Singapore
Clinical Lecturer – Yong Loo Lin School of Medicine, Singapore
Executive Committee Member of SingHealth AI Office
Service Chief, NNI@TTSH Campus - SingHealth Duke-NUS Memory and Cognitive Disorder Centre
Board Member, Chapter of Neurologists, Academy of Medicine, Singapore

Awards

SingHealth GCEO Outstanding Researcher Award - 2025
Singapore Health Quality Service Award, Star - 2024
Singapore Health Quality Service Award, Gold - 2023
NMRC Research Training Fellowship Award - 2021

Research Interests

Cognitive and behavioral aspects of neurocognitive diseases using platforms such as biomarkers, neuroimaging and MedTech.

Publications

For a full list of publications, visit: ‪Kok Pin Ng - ‪Google Scholar

Wilbur Zhi Hao Koh, See Ann Soo, Seyed Ehsan Saffari, Hui Jin Chiew, Adeline Su Lyn Ng, K.P. Ng*, Kandiah, N.*, 2024. Normative data for baseline and longitudinal neuropsychological assessments in Singapore, Ann Acad Med Singap. 2024 Jan 30;53(1):48-52. *Joint Last Authors
Ng, K.P.*, Shen, J.Y.*, Chiew, H.J., Ng, A.S.L., Kandiah, N., Rosa-Neto, P. and Gauthier, S., 2023. White Matter Hyperintensity as a Vascular Contribution to the AT (N) Framework. The Journal of Prevention of Alzheimer's Disease, pp.1-14. *contributed equally
Ng, K.P.*, Qian, X.*, Ng, K.K., Ji, F., Rosa-Neto, P., Gauthier, S., Kandiah, N., Zhou, J.H. and Alzheimer's Disease Neuroimaging Initiative, 2022. Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum. Elife, 11, p.e77745. *contributed equally
Ng, K.P.*, Chiew, H.J.*, Rosa-Neto, P., Kandiah, N., Ismail, Z. and Gauthier, S., 2021. Associations of AT (N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Translational neurodegeneration, 10(1), pp.1-14 *contributed equally
Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Chan, Y.H., Jiang, L., Therriault, J., Benedet, A.L., Shin, M., Kandiah, N., Greenwood, C.M. and Rosa-Neto, P., 2021. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease. Translational Neurodegeneration, 10(1), pp.1-11.

Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., et al. 2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 88(19), pp.1814-1821.
Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., Guiot, M.C., Guo, Q., Harada, R., Comley, R.A. and Massarweh, G., 2017. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimer's Research & Therapy, 9(1), p.25.
Li, X., Ba, M., Ng, K.P., Mathotaarachchi, S., Pascoal, T.A., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
Ng, K.P., Ng, A., Assam, P., Heng, E. and Kandiah, N., 2014. Role of cognitive enhancer therapy in Alzheimer’s disease with concomitant cerebral white matter disease: findings from a long-term naturalistic study. Drugs in R&d, 14(3), pp.195-203.
Ba, M., Li, X., Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3(1), pp.107-113.
Ba, M., Kong, M., Li, X., Ng, K.P., Rosa-Neto, P. and Gauthier, S., 2016. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?. Translational Neurodegeneration, 5(1), p.20.